Auron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic Malignancies

Novel approach targeting KAT2A/B with preclinical validation across multiple cancer models and tumor types

Excerpt from the Press Release:

NEWTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) — Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that the first patient has been dosed with AUTX-703 in a first-in-human, Phase 1 clinical trial for patients with advanced hematologic malignancies (NCT06846606).

AUTX-703 is a novel, first-in-class, orally available KAT2A/B degrader discovered and developed by Auron using its AURIGIN™ Platform. The Company has previously presented preclinical data demonstrating a dose dependent survival advantage with AUTX-703 in a primary acute myeloid leukemia (AML) model.

“The initiation of our first Phase 1 trial marks a significant milestone for Auron in our transition to a clinical-stage company,” said Kate Yen, Chief Executive Officer of Auron Therapeutics. “This achievement reflects the strength of our scientific platform and the dedication of our team in advancing a novel therapeutic approach targeting KAT2A/B – the epigenetic regulators that play a central role in driving cellular plasticity. By modulating this key mechanism, we aim to overcome one of the fundamental barriers to durable cancer treatment. We believe this strategy has the potential to deliver transformative benefits to patients while creating long-term value for our stakeholders.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release